DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. — Investor Relations & Filings
About DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Dizal (Jiangsu) Pharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cancer and autoimmune diseases. Originating from AstraZeneca's Innovation Center China, the company leverages a proprietary translational medicine platform and structure-based drug design capabilities to address unmet medical needs globally. Its portfolio features several clinical-stage assets, notably sunvozertinib, a selective EGFR tyrosine kinase inhibitor for non-small cell lung cancer with Exon20 insertion mutations, and golidocitinib, a JAK1-selective inhibitor for peripheral T-cell lymphoma. Dizal focuses on developing first-in-class and best-in-class medicines through a science-driven approach, maintaining a robust pipeline of small molecule candidates aimed at precision oncology and immunology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 迪哲医药：2025年年度股东会会议资料 | 2026-04-14 | Chinese | |
| 迪哲医药：2022年限制性股票激励计划首次授予的第一类激励对象第三个归属期第二次归属结果暨股票上市公告 | 2026-04-09 | Chinese | |
| 迪哲医药：2025年年度报告摘要 | 2026-03-30 | Chinese | |
| 迪哲医药：会计师事务所履职情况评估报告 | 2026-03-30 | Chinese | |
| 迪哲医药：关于2025年度日常关联交易实施情况与2026年度日常关联交易预计的公告 | 2026-03-30 | Chinese | |
| 迪哲医药：立信会计师事务所（特殊普通合伙）关于迪哲（江苏）医药股份有限公司2025年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2026-03-30 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 34900721 | 迪哲医药：2025年年度股东会会议资料 | 2026-04-14 | Chinese | ||
| 39417039 | 迪哲医药：2022年限制性股票激励计划首次授予的第一类激励对象第三个归属期第二次归属结果暨股票上市公告 | 2026-04-09 | Chinese | ||
| 39417032 | 迪哲医药：2025年年度报告摘要 | 2026-03-30 | Chinese | ||
| 39417020 | 迪哲医药：会计师事务所履职情况评估报告 | 2026-03-30 | Chinese | ||
| 39417018 | 迪哲医药：关于2025年度日常关联交易实施情况与2026年度日常关联交易预计的公告 | 2026-03-30 | Chinese | ||
| 39417008 | 迪哲医药：立信会计师事务所（特殊普通合伙）关于迪哲（江苏）医药股份有限公司2025年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2026-03-30 | Chinese | ||
| 39416924 | 迪哲医药：2025年内部控制评价报告 | 2026-03-30 | Chinese | ||
| 39416918 | 迪哲医药：关于使用部分暂时闲置募集资金临时补充流动资金的公告 | 2026-03-30 | Chinese | ||
| 39416912 | 迪哲医药：董事会审计委员会2025年度履职情况报告 | 2026-03-30 | Chinese | ||
| 39416907 | 迪哲医药：关于使用暂时闲置募集资金进行现金管理的公告 | 2026-03-30 | Chinese | ||
| 39416902 | 迪哲医药：立信会计师事务所（特殊普通合伙）关于迪哲（江苏）医药股份有限公司2025年度募集资金存放与使用情况专项报告的鉴证报告 | 2026-03-30 | Chinese | ||
| 39416578 | 迪哲医药：未来三年（2026年-2028年）股东分红回报规划 | 2026-03-30 | Chinese | ||
| 39416573 | 迪哲医药：2025年度募集资金存放与实际使用情况的专项报告 | 2026-03-30 | Chinese | ||
| 39416567 | 迪哲医药：关于续聘会计师事务所的公告 | 2026-03-30 | Chinese | ||
| 39416562 | 迪哲医药：董事会关于独立董事独立性自查情况的专项报告 | 2026-03-30 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58224/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58224 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58224 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58224 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58224}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (id: 58224)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.